214337-06-1

Upstream product

• 214336-97-7 (3aS,6S,6aR)-6-methyl-5-oxohexahydropyrrolo[3,2-b]pyrrole-1-carboxylic acid benzyl ester 
• 214337-63-0 (c-2,c-3-dimethylcyclopropyl-r-1-carboxylic) anhydride 
• 214337-01-6 (3S,3aR,6aS)-3-methyl-2-oxohexahydropyrrolo[3,2-b]pyrrole-1,4-dicarboxylic acid 4-benzyl ester 1-tert-butyl ester 
• 34669-52-8 (c-2,c-3-dimethylcyclopropyl-r-1-carboxylic) acid 
• 556064-12-1 C₁₁H₁₈O₃ 

Relevant academic research and scientific papers

Design and synthesis of pyrrolidine-5,5′-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability

A series of chiral, (S)-proline-α-methylpyrrolidine-5,5-trans-lactam serine protease inhibitors has been developed as antivirals of human cytomegalovirus (HCMV). The SAR of the functionality on the proline nitrogen has shown that derivatives of para-subst

Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease. Part 3: Potency and plasma stability

Mechanism-based inhibitors of HCMV protease, which are stable to human plasma (≥20 h) and have single-figure potency in the μM range against HCMV protease, have been developed based on the dansylproline α-methyl pyrrolidine-5,5-trans-lactam nucleus.